Literature DB >> 27001012

Bladder cancer: Atezolizumab effective against advanced-stage disease.

Peter Sidaway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27001012     DOI： 10.1038/nrurol.2016.60

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321
  1 in total
  9 in total

Review 1.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

Review 2.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Authors:  Lesley Seymour; Jan Bogaerts; Andrea Perrone; Robert Ford; Lawrence H Schwartz; Sumithra Mandrekar; Nancy U Lin; Saskia Litière; Janet Dancey; Alice Chen; F Stephen Hodi; Patrick Therasse; Otto S Hoekstra; Lalitha K Shankar; Jedd D Wolchok; Marcus Ballinger; Caroline Caramella; Elisabeth G E de Vries
Journal:  Lancet Oncol       Date:  2017-03-02       Impact factor: 41.316

3.  Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway.

Authors:  Denzel Zhu; Emily Barry; Alexander I Sankin
Journal:  Transl Androl Urol       Date:  2019-12

Review 4.  Molecular Imaging of Immunotherapy Targets in Cancer.

Authors:  Emily B Ehlerding; Christopher G England; Douglas G McNeel; Weibo Cai
Journal:  J Nucl Med       Date:  2016-07-28       Impact factor: 10.057

5.  Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.

Authors:  Claudia Ceci; Lucio Tentori; Maria Grazia Atzori; Pedro M Lacal; Elena Bonanno; Manuel Scimeca; Rosella Cicconi; Maurizio Mattei; Maria Gabriella de Martino; Giuseppe Vespasiani; Roberto Miano; Grazia Graziani
Journal:  Nutrients       Date:  2016-11-22       Impact factor: 5.717

6.  Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?

Authors:  Robert O Dillman
Journal:  Hum Vaccin Immunother       Date:  2016-11-03       Impact factor: 3.452

7.  Efficacy of long-term extended nursing services combined with atezolizumab in patients with bladder cancer after endoscopic bladder resection.

Authors:  Yao Song; Pengjuan Ren; Yang Wu; Baodi Zhang; Junrong Wang; Yue Li
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

Review 8.  Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.

Authors:  Bingshan Liu; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2017-12-01       Impact factor: 17.388

9.  Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens.

Authors:  Huihong Xu; Laura Bratton; Michael Nead; Donna Russell; Zhongren Zhou
Journal:  Cytojournal       Date:  2018-12-24       Impact factor: 2.091
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.